Prospective study on stereotactic body radiotherapy for small pancreatic neuroendocrine tumors: tolerance and effectiveness analysis

期刊论文
发表日期：

2024年6月22日

查看全文

Mercedes López Gonzalez,
Ovidio Hernando-Requejo,
Raquel Ciervide Jurío,
Ángel Montero Luis,
Carmen Saiz Guisasola,
Emilio Sánchez Saugar,
Beatriz Álvarez Rodríguez,
Xin Chen-Zhao,
Mariola García-Aranda,
Jeannette Valero Albarran,
Rosa Alonso Gutierrez,
Lina García Cañamaque,
Susana Prados,
Yolanda Quijano,
Emilio de Vicente,
Carmen Rubio

摘要

Introduction

Surgery is the standard treatment for pancreatic neuroendocrine tumors (pNETs), obtaining favorable results but associating high morbidity and mortality rates. This study assesses stereotactic body radiation therapy (SBRT) as a radical approach for small (< 2 cm) nonfunctioning pNETs.

Materials and methods

From January 2017 to June 2023, 20 patients with small pNETs underwent SBRT in an IRB-approved study. Endpoints included local control, tolerance, progression-free survival, and overall survival (OS). Diagnostic assessments comprised endoscopy, CT scans, OctreScan or PET-Dotatoc, abdominal MRI, and histological confirmatory samples.

Results

In a 30-month follow-up of 20 patients (median age 55.5 years), SBRT was well-tolerated with no grade > 2 toxicity. 40% showed morphological response, 55% remained stable. Metabolically, 50% achieved significant improvement. With a median OS of 41.5 months, all patients were alive without local or distant progression or need for surgical resection.

Conclusion

SBRT is a feasible and well-tolerated approach for small neuroendocrine pancreatic tumors, demonstrating effective local control. Further investigations are vital for validation and extension of these findings.